RetaMaps

HCG Diet Nj

HCG Diet Nj · 51 John F Kennedy Parkway · Millburn, NJ 07078

4.7· 6 Google reviews

Listing updated October 2, 2026

Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

Care described on the practice's website

  • GLP-1 medications named on site
  • Medically supervised weight loss

About this practice

HCG Diet Nj is a New Jersey weight-loss practice with a Millburn listing and a website that describes a physician-monitored program with offices in Voorhees and Fairfield, including office visits, a 24/7 nurse hotline and Dr. Daniel Olivero, MD. The listing shows telehealth and includes semaglutide and tirzepatide among its services. Google reviews for the Millburn listing date back to 2014, with a 4.7-star rating across 6 reviews and none in the past year; reviewers mention the staff and results.

Services & access

Advertises semaglutide todayYes
Advertises tirzepatide todayYes
Telehealth visitsYes
Cash pay accepted—
Accepts insurance — per practice websiteYes
Accepting new patients — per practice websiteYes

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Review activity

★ 4.7
Google rating · 6 reviews

Counts computed by RetaMaps from public Google reviews; most recent review 2018-03-28. Read the reviews themselves on the practice's Google listing.

What patients say

Rated ★4.7 across 6 Google reviews. Of the 6 reviews we analyzed, 6 (100%) are positive (4–5★) and 0 (0%) are negative (1–2★).

What patients like

  • Friendly, helpful staff4 reviews
  • Weight-loss results2 reviews

Common complaints

No negative reviews among those we analyzed.

5★
4
4★
2
3★
0
2★
0
1★
0

Most recent Google reviews

Diana M.★★★★★2018-03-28

The staff is very knowledgeable... I lost 24 lb in 4 weeks. Very happy with results. Jim is amazing. Always answers if I had any questions.

First★★★★★2017-01-21

One of the best experience thus far. Day 1 for me so I texted a million questions and I get rapid responses. Very informative, very personable, courteous and caring! I'm still amazed with the staff. Will give another review in a week. I trust this is the best health decision thus far. 🙏🏼

Peggy F.★★★★★2014-12-04

I learned about the HCG Diet Center by searching the internet and come across the HCG Diet Center in NJ. I had made a decision to try it when I saw Dr Oz talking about it. Since this was medically supervise I decided to try it. I did the 25 days and I have to say that I did lose at least 20 pounds within the 25 days. I was skeptical but the diet really works if you just stick to it. The office is very clean and friendly. The staff spends time with you and tell you about the program. I am going to do it again. I text with all and any questions and get a prompt response.

Tabatha (.★★★★★2014-12-01

I decided to try the 40 day HCG diet plan and lost a whole 38 pounds!! The entire staff was very friendly, helpful and accommodating. I referred two friends after they saw how fast I lost weight and they had amazing results also! Thank you again for helping us get on track to being healthy again!

Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.

Nearby providers in Millburn

Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs